Skip to main content
Skip to main content
GRVI logo

Upexi, Inc. (GRVI) Stock Analysis

DELISTED 2022

What happened to Upexi, Inc. (GRVI) stock?

Upexi, Inc. (GRVI) no longer trades on public markets. It was delisted in August 2022. The figures below are historical and are not a current quote.

MCap: $88.9M| Vol: 30.4K|
Data from FMP · Methodology

For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Upexi, Inc. (GRVI) trades at $4.95. Upexi, Inc. focuses on developing, producing, and selling cannabidiol (CBD) products. The company targets consumer markets, including botanical, beauty care, pet care, and functional food sectors. Market cap: $88.9M, Sector: Healthcare.

Last analyzed: Mar 18, 2026
Upexi, Inc. focuses on developing, producing, and selling cannabidiol (CBD) products. The company targets consumer markets, including botanical, beauty care, pet care, and functional food sectors.

Analyst Coverage for GRVI: GRVI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GRVI against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.

Watch the GRVI film Every key number, told as a short cinematic story — just press play. ~2 min
Council Score · Weighted Average of 3 Disciplines
Split View 43/100 · C

GRVI: the 2 scored disciplines are evenly split. Dominant signal: Ken Griffin bearish.

How is this calculated? →
Legends Council · 5 Legends + Moon AI
Ray Dalio
Bullish
Ken Griffin
Bearish
Jim Simons
Neutral
Izzy Englander
Bearish
Seth Klarman
Bearish
Moon AI
Neutral
Munger's Mindset · Balance Sheet & Valuation
Financial Health
Weak
Margin of Safety
Fairly Valued
Council Score · Weighted Average of 3 Disciplines · See tabs for details →

Upexi, Inc. (GRVI) Healthcare & Pipeline Overview

CEOAllan J. Marshall
Employees122
HeadquartersHenderson, US
IPO Year2021

Upexi, Inc. (GRVI) operates in the specialty and generic drug manufacturing sector, focusing on cannabidiol (CBD) products. The company develops, produces, and markets raw materials, white label products, and end consumer goods, serving diverse markets such as botanical, beauty, pet care, and functional foods.

Data Provenance | Financial Data Quantitative Analysis Analysis: Mar 18, 2026

What Is the Investment Thesis for GRVI?

As of Mar 18, 2026 — figures reflect the data available on that date.

Upexi, Inc. presents a speculative investment opportunity within the high-growth CBD market. The company's diverse product offerings across botanical, beauty, pet care, and functional food sectors provide multiple revenue streams. However, the company's negative P/E ratio of -0.57 and a profit margin of -496.9% indicate significant challenges in achieving profitability. A key driver for future growth will be Upexi's ability to scale its operations and improve its cost structure. The company's gross margin of 80.0% suggests potential for profitability if operational efficiencies can be achieved. Investors should closely monitor Upexi's progress in expanding its market share and achieving sustainable profitability in the competitive CBD landscape.

Based on FMP financials and quantitative analysis

GRVI Key Highlights

Market capitalization of $88.9M reflects its small-cap status and potential for volatility.

  • Negative P/E ratio of -0.57 indicates the company is currently not profitable.
  • Gross margin of 80.0% suggests strong potential for profitability if operational costs are managed effectively.
  • Profit margin of -496.9% highlights significant challenges in achieving profitability.
  • The company operates an annual CBD industry tradeshow, providing a platform for networking and business development.

Who Are GRVI's Competitors?

GRVI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap AI Score
AADI Aadi Bioscience, Inc. $2.05 -2.38% $94.9M 50
ASXC Asensus Surgical, Inc. $0.35 +0.64% $94.9M 53
BLI Berkeley Lights, Inc. $1.20 -5.88% $86.6M 51
IMDX Insight Molecular Diagnostics Inc. $4.38 +2.34% $141M
LIEN Chicago Atlantic BDC, Inc. $9.74 +2.53% $223M 86
SHIEF Shield Therapeutics plc $0.07 +0.00% $75.3M 62
MNNGF Baijin Life Science Holdings Limited $0.08 +0.00% $74.6M 63
CNVCF BioHarvest Sciences Inc. $6.30 +0.00% $109M 66

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are GRVI's Key Strengths?

Diverse product offerings across multiple consumer markets.

  • Vertically integrated operations.
  • Established presence in the CBD industry.
  • High gross margin of 80.0%.

What Are GRVI's Weaknesses?

Negative P/E ratio and profit margin.

  • Limited brand recognition compared to larger competitors.
  • Dependence on the regulatory environment for CBD products.
  • Small market capitalization.

What Could Drive GRVI Stock Higher?

Potential regulatory changes in the CBD industry could create new market opportunities or challenges.

  • Expansion of product offerings into new consumer markets.
  • Increased brand awareness and marketing efforts to drive sales growth.
  • Strategic partnerships and acquisitions to expand market reach.

What Are the Key Risks for GRVI?

Financial-distress signal — its Altman Z-Score of -0.29 sits in the distress zone (elevated bankruptcy risk).

  • Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
  • Intense competition from established players and new entrants in the CBD market.
  • Regulatory uncertainty surrounding CBD products could impact the company's operations.
  • Fluctuations in the price of raw materials could affect the company's profitability.
  • Negative P/E ratio and profit margin indicate financial instability.

What Are the Growth Opportunities for GRVI?

  • Expansion into new geographic markets: Upexi can pursue growth by expanding its distribution network into new geographic markets, both domestically and internationally. The global CBD market is projected to reach $55.79 billion by 2028, presenting significant opportunities for companies with a strong brand and distribution capabilities. Timeline: Within the next 2-3 years.
  • Development of innovative CBD products: Upexi can invest in research and development to create innovative CBD products that cater to specific consumer needs and preferences. This could include new formulations, delivery methods, or product categories. The market for novel CBD products is expected to grow as consumers become more knowledgeable about the potential benefits of CBD. Timeline: Ongoing.
  • Strategic partnerships and acquisitions: Upexi can pursue strategic partnerships and acquisitions to expand its product portfolio, market reach, and technological capabilities. This could involve partnering with established players in the botanical, beauty, pet care, or functional food sectors. Timeline: Within the next 1-2 years.
  • Increased focus on online sales and marketing: Upexi can enhance its online sales and marketing efforts to reach a wider audience and drive revenue growth. This could involve investing in search engine optimization (SEO), social media marketing, and e-commerce platforms. The online CBD market is experiencing rapid growth, providing significant opportunities for companies with a strong online presence. Timeline: Ongoing.
  • Capitalizing on the growing pet CBD market: The pet CBD market is a rapidly expanding segment within the broader CBD industry. Upexi can leverage its existing pet care product line to capitalize on this trend by developing and marketing new CBD-infused products specifically for pets. This includes treats, oils, and topical applications designed to address various pet health concerns. Timeline: Within the next year.

What Are GRVI's Competitive Advantages?

  • Vertically integrated operations from raw materials to end products.
  • Diversified product offerings across multiple consumer markets.
  • Proprietary formulations and manufacturing processes.
  • Established presence in the CBD industry with brand recognition.

What Does GRVI Do?

Upexi, Inc., originally incorporated in 2018 and headquartered in Henderson, Nevada, operates through its subsidiaries to develop, produce, market, and sell a range of products containing cannabidiol (CBD). The company's business revolves around the industrial hemp plant extract, catering to several consumer markets. These markets include the botanical sector, where CBD is used in various plant-based products; the beauty care sector, incorporating CBD into skincare and cosmetic products; the pet care sector, offering CBD-infused products for animals; and the functional food sector, where CBD is added to edible products for its purported health benefits. Upexi also engages in the raw materials and white label product segments, providing CBD ingredients and ready-to-brand products to other businesses. Furthermore, Upexi operates an annual tradeshow related to the CBD industry in the United States, facilitating networking and business opportunities within the sector. The company's vertically integrated approach, from raw material sourcing to end-consumer product sales, allows it to maintain control over quality and supply chain efficiency. Upexi's focus on diverse consumer markets provides multiple avenues for revenue generation and growth within the expanding CBD industry.

What Products and Services Does GRVI Offer?

  • Develops and produces raw materials containing cannabidiol (CBD).
  • Creates white label CBD products for other businesses.
  • Markets and sells end consumer products containing CBD.
  • Serves consumer markets including botanical, beauty care, and pet care.
  • Offers functional food products infused with CBD.
  • Operates an annual tradeshow related to the CBD industry in the United States.

How Does GRVI Make Money?

  • Develops and manufactures CBD-based products.
  • Sells products directly to consumers through online and retail channels.
  • Provides white-label CBD products to other businesses.
  • Generates revenue through tradeshow operations.

What Industry Does GRVI Operate In?

Upexi, Inc. operates within the rapidly evolving CBD industry, which has experienced significant growth due to increasing consumer awareness and acceptance of CBD products. The market is characterized by a fragmented competitive landscape, with numerous companies offering a wide range of CBD-infused products. Upexi's focus on diverse consumer markets, including botanical, beauty, pet care, and functional food sectors, positions it to capitalize on various growth trends within the industry. However, the company faces challenges related to regulatory uncertainty and intense competition from both established players and new entrants.

Who Are GRVI's Key Customers?

  • Consumers seeking botanical products containing CBD.
  • Customers in the beauty care sector looking for CBD-infused products.
  • Pet owners interested in CBD products for their animals.
  • Individuals seeking functional food products with CBD.
  • Businesses seeking white-label CBD products to brand and sell.
AI Confidence: 71% Updated: Mar 18, 2026

Company Profile

Upexi, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Henderson, US. The company is led by CEO Allan J. Marshall. GRVI has traded publicly since 2021.

How Upexi, Inc. Is Valued

Upexi, Inc. carries a market capitalization of $88.9M, placing it in the micro-cap category.

Key Financial Metrics

Its free cash flow yield is -39.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.72 indicates the company holds enough short-term assets to cover its near-term obligations.

F-Score 3/9

Financial Health

Upexi, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.29 places it in the distress zone, a signal of elevated financial risk.

Net selling

Insider Activity

The most recent 12 insider filings for Upexi, Inc. break down as 7 sales and 5 purchases. On net that is roughly 822K shares disposed (about $765K), a signal worth weighing alongside the fundamentals.

GRVI Financials

Fundamental Snapshot

Return on Equity (TTM)
-307.0%
Current Ratio
1.7

Based on FMP financials and quantitative analysis

Bull Case vs Bear Case

Bull Case

  • Insiders seem to be positioning themselves for potential growth, which often signals confidence from those who know the company best.
  • The overall market perception seems to be improving, suggesting that the company might be gaining traction in the eyes of investors.
  • Community sentiment is leaning towards a positive outlook, indicating that more people are seeing potential upside in the near future.
  • Recent developments suggest the company is making strategic moves that could positively impact its long-term performance.

Bear Case

  • Recent insider activity could also be interpreted as a move to secure profits, not necessarily a sign of future growth.
  • Despite some improvements, market perception remains cautious, and the company is still facing headwinds.
  • Bearish community views highlight concerns about the company's ability to execute its plans effectively.
  • Recent market developments might present challenges that could hinder the company's progress, creating uncertainty.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026

GRVI Latest News

Leadership: Allan J. Marshall

CEO

Allan J. Marshall serves as the CEO of Upexi, Inc., managing a workforce of 122 employees. Information regarding his detailed career history, education, and previous roles is not available in the provided data. However, as CEO, he is responsible for the overall strategic direction and operational execution of the company.

Track Record: Due to the limited information available, specific achievements, strategic decisions, and company milestones under Allan J. Marshall's leadership cannot be detailed. His tenure and impact on the company's performance require further data and analysis.

Common Questions About GRVI (Healthcare)

What happened to Upexi, Inc. (GRVI) stock?

Upexi, Inc. (GRVI) no longer trades on public markets. It was delisted in August 2022. The figures below are historical and are not a current quote.

Can I still buy GRVI shares?

No. GRVI stopped trading on public markets in August 2022, so the shares are not available through a broker. Anything you see quoted for GRVI elsewhere is historical data, not a live market.

Are the figures on this page current?

No. Every number here is the last value recorded before GRVI stopped trading. Nothing on this page updates, and none of it is a current quote.

Why does this page still exist?

Because people still search for what happened to Upexi, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.

What does Upexi, Inc. do?

Upexi, Inc. operates in the healthcare sector, specifically focusing on the development, production, marketing, and sale of cannabidiol (CBD) products. Through its subsidiaries, the company engages in creating raw materials, white label products, and end consumer goods containing CBD. These products cater to diverse consumer markets, including botanical, beauty care, pet care, and functional food sectors.

What are the key growth opportunities for GRVI in healthcare?

Upexi, Inc. can expand its presence in the healthcare sector by developing new CBD-based therapies and products targeting specific medical conditions. This includes exploring partnerships with healthcare providers and research institutions to conduct clinical trials and validate the efficacy of its products.

What revenue streams does Upexi, Inc. have in healthcare?

Upexi, Inc.'s revenue streams in the healthcare sector are primarily derived from the sale of CBD-based products across various consumer markets. These include botanical products, beauty care items, pet care products, and functional foods, all infused with CBD. The company generates revenue through direct-to-consumer sales via online and retail channels, as well as through white-label partnerships with other businesses.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Analysis updated
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Information is based on available data and may be subject to change.
  • AI analysis is pending for GRVI, which may provide further insights.
Data Sources

Popular Stocks

More Stocks We Cover